Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The progno...
Gespeichert in:
| Veröffentlicht in: | Blood 2016-06, Vol.127 (24), p.2955-2962 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2962 |
|---|---|
| container_issue | 24 |
| container_start_page | 2955 |
| container_title | Blood |
| container_volume | 127 |
| creator | Sonneveld, Pieter Avet-Loiseau, Hervé Lonial, Sagar Usmani, Saad Siegel, David Anderson, Kenneth C. Chng, Wee-Joo Moreau, Philippe Attal, Michel Kyle, Robert A. Caers, Jo Hillengass, Jens San Miguel, Jesús van de Donk, Niels W.C.J. Einsele, Hermann Bladé, Joan Durie, Brian G.M. Goldschmidt, Hartmut Mateos, María-Victoria Palumbo, Antonio Orlowski, Robert |
| description | The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities. However, to achieve this, consensus on definitions of analytical techniques, proportion of abnormal cells, and treatment regimens is needed. Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-free survival in t(4;14) and del(17/17p). Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification. |
| doi_str_mv | 10.1182/blood-2016-01-631200 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_liege</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4920674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712034458X</els_id><sourcerecordid>27002115</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-12ac5bfa99a3b6929d308c17857444baadb1acf62730cea1a90eaa13947f40c3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhy0EokvhDRDyCwTGjvOPAxKqoFQq4rISR2viTBLTxF5sZ6t9e7K7pcCFk0eyv9945mPstYC3QtTyXTt532USRJmByMpcSIAnbCMKWWcAEp6yDQCUmWoqccFexPgDQKhcFs_ZhazWF0IUG_ZzGwjTTC5x3_N5mZLdTcTnA01-Rn5v08hHO4xZsPGOm0PyAzlK1sT3HLnxLpKLSzzCaSR-4xIFh8l6hxP_-pDy3Yc76wZ-Hfyye8me9ThFevVwXrLt50_bqy_Z7bfrm6uPt5kpoEqZkGiKtsemwbwtG9l0OdRGVHVRKaVaxK4VaPpSVjkYQoENEKLIG1X1Ckx-yT6cY3dLO1Nn1gkDTnoX7IzhoD1a_e-Ns6Me_F6rRkJZqTUgPwdMlgbSPrRW7-UJPNXLNGg0uiUtZVlr0VR5UayUOlMm-BgD9Y8dBeijN33ypo_eNAh99rZib_7-7SP0W9SfcWhd2d5S0NFYcoY6G8gk3Xn7_w6_AKGlrT0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Sonneveld, Pieter ; Avet-Loiseau, Hervé ; Lonial, Sagar ; Usmani, Saad ; Siegel, David ; Anderson, Kenneth C. ; Chng, Wee-Joo ; Moreau, Philippe ; Attal, Michel ; Kyle, Robert A. ; Caers, Jo ; Hillengass, Jens ; San Miguel, Jesús ; van de Donk, Niels W.C.J. ; Einsele, Hermann ; Bladé, Joan ; Durie, Brian G.M. ; Goldschmidt, Hartmut ; Mateos, María-Victoria ; Palumbo, Antonio ; Orlowski, Robert</creator><creatorcontrib>Sonneveld, Pieter ; Avet-Loiseau, Hervé ; Lonial, Sagar ; Usmani, Saad ; Siegel, David ; Anderson, Kenneth C. ; Chng, Wee-Joo ; Moreau, Philippe ; Attal, Michel ; Kyle, Robert A. ; Caers, Jo ; Hillengass, Jens ; San Miguel, Jesús ; van de Donk, Niels W.C.J. ; Einsele, Hermann ; Bladé, Joan ; Durie, Brian G.M. ; Goldschmidt, Hartmut ; Mateos, María-Victoria ; Palumbo, Antonio ; Orlowski, Robert</creatorcontrib><description>The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities. However, to achieve this, consensus on definitions of analytical techniques, proportion of abnormal cells, and treatment regimens is needed. Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-free survival in t(4;14) and del(17/17p). Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification.</description><identifier>ISSN: 0006-4971</identifier><identifier>ISSN: 1528-0020</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2016-01-631200</identifier><identifier>PMID: 27002115</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bortezomib ; Chromosome Aberrations - classification ; Combined Modality Therapy ; Consensus ; Cytogenetics ; Hematology ; Hematopoietic Stem Cell Transplantation ; Human health sciences ; Humans ; Hématologie ; Lenalidomide ; Multiple Myeloma - classification ; Multiple Myeloma - genetics ; Multiple Myeloma - mortality ; Multiple Myeloma - therapy ; Prognosis ; Risk Factors ; Sciences de la santé humaine ; Thalidomide - analogs & derivatives ; Transplantation, Autologous</subject><ispartof>Blood, 2016-06, Vol.127 (24), p.2955-2962</ispartof><rights>2016 American Society of Hematology</rights><rights>2016 by The American Society of Hematology.</rights><rights>2016 by The American Society of Hematology 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-12ac5bfa99a3b6929d308c17857444baadb1acf62730cea1a90eaa13947f40c3</citedby><cites>FETCH-LOGICAL-c507t-12ac5bfa99a3b6929d308c17857444baadb1acf62730cea1a90eaa13947f40c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27002115$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sonneveld, Pieter</creatorcontrib><creatorcontrib>Avet-Loiseau, Hervé</creatorcontrib><creatorcontrib>Lonial, Sagar</creatorcontrib><creatorcontrib>Usmani, Saad</creatorcontrib><creatorcontrib>Siegel, David</creatorcontrib><creatorcontrib>Anderson, Kenneth C.</creatorcontrib><creatorcontrib>Chng, Wee-Joo</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>Attal, Michel</creatorcontrib><creatorcontrib>Kyle, Robert A.</creatorcontrib><creatorcontrib>Caers, Jo</creatorcontrib><creatorcontrib>Hillengass, Jens</creatorcontrib><creatorcontrib>San Miguel, Jesús</creatorcontrib><creatorcontrib>van de Donk, Niels W.C.J.</creatorcontrib><creatorcontrib>Einsele, Hermann</creatorcontrib><creatorcontrib>Bladé, Joan</creatorcontrib><creatorcontrib>Durie, Brian G.M.</creatorcontrib><creatorcontrib>Goldschmidt, Hartmut</creatorcontrib><creatorcontrib>Mateos, María-Victoria</creatorcontrib><creatorcontrib>Palumbo, Antonio</creatorcontrib><creatorcontrib>Orlowski, Robert</creatorcontrib><title>Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group</title><title>Blood</title><addtitle>Blood</addtitle><description>The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities. However, to achieve this, consensus on definitions of analytical techniques, proportion of abnormal cells, and treatment regimens is needed. Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-free survival in t(4;14) and del(17/17p). Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bortezomib</subject><subject>Chromosome Aberrations - classification</subject><subject>Combined Modality Therapy</subject><subject>Consensus</subject><subject>Cytogenetics</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Human health sciences</subject><subject>Humans</subject><subject>Hématologie</subject><subject>Lenalidomide</subject><subject>Multiple Myeloma - classification</subject><subject>Multiple Myeloma - genetics</subject><subject>Multiple Myeloma - mortality</subject><subject>Multiple Myeloma - therapy</subject><subject>Prognosis</subject><subject>Risk Factors</subject><subject>Sciences de la santé humaine</subject><subject>Thalidomide - analogs & derivatives</subject><subject>Transplantation, Autologous</subject><issn>0006-4971</issn><issn>1528-0020</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQhy0EokvhDRDyCwTGjvOPAxKqoFQq4rISR2viTBLTxF5sZ6t9e7K7pcCFk0eyv9945mPstYC3QtTyXTt532USRJmByMpcSIAnbCMKWWcAEp6yDQCUmWoqccFexPgDQKhcFs_ZhazWF0IUG_ZzGwjTTC5x3_N5mZLdTcTnA01-Rn5v08hHO4xZsPGOm0PyAzlK1sT3HLnxLpKLSzzCaSR-4xIFh8l6hxP_-pDy3Yc76wZ-Hfyye8me9ThFevVwXrLt50_bqy_Z7bfrm6uPt5kpoEqZkGiKtsemwbwtG9l0OdRGVHVRKaVaxK4VaPpSVjkYQoENEKLIG1X1Ckx-yT6cY3dLO1Nn1gkDTnoX7IzhoD1a_e-Ns6Me_F6rRkJZqTUgPwdMlgbSPrRW7-UJPNXLNGg0uiUtZVlr0VR5UayUOlMm-BgD9Y8dBeijN33ypo_eNAh99rZib_7-7SP0W9SfcWhd2d5S0NFYcoY6G8gk3Xn7_w6_AKGlrT0</recordid><startdate>20160616</startdate><enddate>20160616</enddate><creator>Sonneveld, Pieter</creator><creator>Avet-Loiseau, Hervé</creator><creator>Lonial, Sagar</creator><creator>Usmani, Saad</creator><creator>Siegel, David</creator><creator>Anderson, Kenneth C.</creator><creator>Chng, Wee-Joo</creator><creator>Moreau, Philippe</creator><creator>Attal, Michel</creator><creator>Kyle, Robert A.</creator><creator>Caers, Jo</creator><creator>Hillengass, Jens</creator><creator>San Miguel, Jesús</creator><creator>van de Donk, Niels W.C.J.</creator><creator>Einsele, Hermann</creator><creator>Bladé, Joan</creator><creator>Durie, Brian G.M.</creator><creator>Goldschmidt, Hartmut</creator><creator>Mateos, María-Victoria</creator><creator>Palumbo, Antonio</creator><creator>Orlowski, Robert</creator><general>Elsevier Inc</general><general>American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>Q33</scope><scope>5PM</scope></search><sort><creationdate>20160616</creationdate><title>Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group</title><author>Sonneveld, Pieter ; Avet-Loiseau, Hervé ; Lonial, Sagar ; Usmani, Saad ; Siegel, David ; Anderson, Kenneth C. ; Chng, Wee-Joo ; Moreau, Philippe ; Attal, Michel ; Kyle, Robert A. ; Caers, Jo ; Hillengass, Jens ; San Miguel, Jesús ; van de Donk, Niels W.C.J. ; Einsele, Hermann ; Bladé, Joan ; Durie, Brian G.M. ; Goldschmidt, Hartmut ; Mateos, María-Victoria ; Palumbo, Antonio ; Orlowski, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-12ac5bfa99a3b6929d308c17857444baadb1acf62730cea1a90eaa13947f40c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bortezomib</topic><topic>Chromosome Aberrations - classification</topic><topic>Combined Modality Therapy</topic><topic>Consensus</topic><topic>Cytogenetics</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Human health sciences</topic><topic>Humans</topic><topic>Hématologie</topic><topic>Lenalidomide</topic><topic>Multiple Myeloma - classification</topic><topic>Multiple Myeloma - genetics</topic><topic>Multiple Myeloma - mortality</topic><topic>Multiple Myeloma - therapy</topic><topic>Prognosis</topic><topic>Risk Factors</topic><topic>Sciences de la santé humaine</topic><topic>Thalidomide - analogs & derivatives</topic><topic>Transplantation, Autologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sonneveld, Pieter</creatorcontrib><creatorcontrib>Avet-Loiseau, Hervé</creatorcontrib><creatorcontrib>Lonial, Sagar</creatorcontrib><creatorcontrib>Usmani, Saad</creatorcontrib><creatorcontrib>Siegel, David</creatorcontrib><creatorcontrib>Anderson, Kenneth C.</creatorcontrib><creatorcontrib>Chng, Wee-Joo</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>Attal, Michel</creatorcontrib><creatorcontrib>Kyle, Robert A.</creatorcontrib><creatorcontrib>Caers, Jo</creatorcontrib><creatorcontrib>Hillengass, Jens</creatorcontrib><creatorcontrib>San Miguel, Jesús</creatorcontrib><creatorcontrib>van de Donk, Niels W.C.J.</creatorcontrib><creatorcontrib>Einsele, Hermann</creatorcontrib><creatorcontrib>Bladé, Joan</creatorcontrib><creatorcontrib>Durie, Brian G.M.</creatorcontrib><creatorcontrib>Goldschmidt, Hartmut</creatorcontrib><creatorcontrib>Mateos, María-Victoria</creatorcontrib><creatorcontrib>Palumbo, Antonio</creatorcontrib><creatorcontrib>Orlowski, Robert</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Université de Liège - Open Repository and Bibliography (ORBI)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sonneveld, Pieter</au><au>Avet-Loiseau, Hervé</au><au>Lonial, Sagar</au><au>Usmani, Saad</au><au>Siegel, David</au><au>Anderson, Kenneth C.</au><au>Chng, Wee-Joo</au><au>Moreau, Philippe</au><au>Attal, Michel</au><au>Kyle, Robert A.</au><au>Caers, Jo</au><au>Hillengass, Jens</au><au>San Miguel, Jesús</au><au>van de Donk, Niels W.C.J.</au><au>Einsele, Hermann</au><au>Bladé, Joan</au><au>Durie, Brian G.M.</au><au>Goldschmidt, Hartmut</au><au>Mateos, María-Victoria</au><au>Palumbo, Antonio</au><au>Orlowski, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2016-06-16</date><risdate>2016</risdate><volume>127</volume><issue>24</issue><spage>2955</spage><epage>2962</epage><pages>2955-2962</pages><issn>0006-4971</issn><issn>1528-0020</issn><eissn>1528-0020</eissn><abstract>The International Myeloma Working Group consensus updates the definition for high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities such as t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q) were identified that confer poor prognosis. The prognosis of patients showing these abnormalities may vary with the choice of therapy. Treatment strategies have shown promise for HR cytogenetic diseases, such as proteasome inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immunotherapy with lenalidomide or pomalidomide. Careful analysis of cytogenetic subgroups in trials comparing different treatments remains an important goal. Cross-trial comparisons may provide insight into the effect of new drugs in patients with cytogenetic abnormalities. However, to achieve this, consensus on definitions of analytical techniques, proportion of abnormal cells, and treatment regimens is needed. Based on data available today, bortezomib and carfilzomib treatment appear to improve complete response, progression-free survival, and overall survival in t(4;14) and del(17/17p), whereas lenalidomide may be associated with improved progression-free survival in t(4;14) and del(17/17p). Patients with multiple adverse cytogenetic abnormalities do not benefit from these agents. FISH data are implemented in the revised International Staging System for risk stratification.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27002115</pmid><doi>10.1182/blood-2016-01-631200</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2016-06, Vol.127 (24), p.2955-2962 |
| issn | 0006-4971 1528-0020 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4920674 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bortezomib Chromosome Aberrations - classification Combined Modality Therapy Consensus Cytogenetics Hematology Hematopoietic Stem Cell Transplantation Human health sciences Humans Hématologie Lenalidomide Multiple Myeloma - classification Multiple Myeloma - genetics Multiple Myeloma - mortality Multiple Myeloma - therapy Prognosis Risk Factors Sciences de la santé humaine Thalidomide - analogs & derivatives Transplantation, Autologous |
| title | Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T02%3A05%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_liege&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20multiple%20myeloma%20with%20high-risk%20cytogenetics:%20a%20consensus%20of%20the%20International%20Myeloma%20Working%20Group&rft.jtitle=Blood&rft.au=Sonneveld,%20Pieter&rft.date=2016-06-16&rft.volume=127&rft.issue=24&rft.spage=2955&rft.epage=2962&rft.pages=2955-2962&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2016-01-631200&rft_dat=%3Cpubmed_liege%3E27002115%3C/pubmed_liege%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27002115&rft_els_id=S000649712034458X&rfr_iscdi=true |